// App-Quantinova.ai

2105 : Unmanipulated Graft Haploindentical Allogeneic Stem Cell Transplantation (Haplo-SCT) In Acute Leukemia: A Long-Term Follow-Up Survey On Behalf Of The Acute Leukemia Working Party (ALWP) Of The European Group For Blood and Marrow Transplantation (EBMT)

Researchers

Presenter

  • Simona Piemontese

Principal Investigators

  • Fabio Ciceri

  • Myriam Labopin

  • Johanna Tischer

  • William Arcese

  • Mohamad Mohty

  • Norbert Claude Gorin

  • He Huang

  • Paolo Di Bartolomeo

  • Depei Wu

  • Dietrich Beelen

  • Yener Koc

  • Boris V Afanasyev

  • Andrea Bacigalupo

Medical Centers

  • Jiangsu Institute of Hematology, Soochow University, Suzhou, China

  • department of Hematology and Cell therapy, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France

  • Stem Cell Transplant Unit, Policlinico Universitario Tor Vergata, Rome, Italy,

  • Medical Park Hospitals Stem Cell Transplant Unit, Antalya, Turkey

  • EBMT Acute Leukemia Working Party and Registry, Saint-Antoine Hospital, Paris, France

  • Bone Marrow Transplantation Center, , the First Affiliated Hospital, Zhejiang University School of Medicine,

  • Hematology - Bone Marrow Transplant Center, Spirito Santo Hospital, Pescara, Italy,

  • Dept of Hematology Oncology, Ospedale San Martino, Genoa, Italy

  • Raisa Gorbacheva Memorial Institute of Children Hematology and Transplantation, St Petersburg State Pavlov Medical University, St Petersburg, Russia

  • Ludwig-Maximilians University of Munich, Campus Grosshadern, Department of Internal Medicine III, Munich, Germany

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Department of Stem Cell Transplantation, University of Essen, Essen, Germany,

Locations

  • China

  • Italy

  • Germany

  • Turkey

  • France

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

Drug/Treatment

  • Alemtuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved